查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1631213

生技药品契约製造市场规模、份额、趋势分析报告：按产品、适应症、地区、细分市场预测，2025-2030 年

Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (MABs, Recombinant Protein), By Indication (Oncology, CVDs), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

生技药品契约製造市场的成长与趋势

根据 Grand View Research, Inc. 的一份新报告，全球生技药品契约製造市场规模预计将到 2030 年达到 575.9 亿美元，2025 年至 2030 年期间的复合年增长率为 10.3%。全球市场在新冠疫情期间高效率成长。这是由于活性化了对 COVID-19 疫苗的研发活动。此外，还扩大了生产设施，以遏制感染的蔓延。例如，2021年11月，龙沙宣布决定扩建其位于瑞士的微生物学开发实验室，以支持公司即将进行的计划。

预计疫情过后将发生许多根本性变化。我们将看到针对冠状病毒的疫苗和治疗方法的生产和製造力度加大，所有业务部门的数位化能力也将增强。这些努力将有助于与製药公司製定共同规划，建立更具策略性的伙伴关係。例如，2022 年 1 月，Lonza 宣布了一项用于发现和设计特异性抗体的技术，称为 bYlok(TM)。全球製药和生技药品製造的外包正在迅速成长。

製药和生物技术公司正在降低与生产药品和生技药品相关的营运成本，同时专注于其核心计划。受託製造厂商(CMO) 具有执行整个製造过程的专业知识和经验。生技药品的内部製造具有挑战性，因为它是一个复杂且资源密集的过程。透过专注于改善药物发现过程，CMO 可以弥合需求和供应之间的差距，从而更快地将生技药品送到患者手中。因此，外包正在迅速成长。

生技药品契约製造市场报告重点

  • 根据产品，MAB 部门预计将在 2024 年占据最大的收入份额，因为 MAB 用于治疗多种疾病，包括癌症、感染疾病、气喘和自体免疫疾病。
  • 根据适应症，肿瘤学在 2024 年占据市场主导地位，收益占有率最大。该部分份额较高的主要因素是癌症患者数量的增加。
  • 由于製药和生技药品製造外包服务的增加以及高昂的研发成本，北美在 2024 年占据了全球市场的主导地位。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章生物製药契约製造市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析 – 波特五力分析
    • PESTLE分析

第 4 章生物製药契约製造市场：产品业务分析

  • 2024 年及 2030 年产品市场占有率
  • 产品细分仪表板
  • 2018 年至 2030 年按产品分類的市场规模、预测与趋势分析
  • 单株抗体（mAb）
  • 重组蛋白
  • 疫苗
  • 反义、RNAi 和分子治疗
  • 其他的

第五章生物製药契约製造市场：适应症业务分析

  • 2024 年和 2030 年指示市场占有率
  • 指示细分仪表板
  • 2018 年至 2030 年按适应症分類的市场规模、预测与趋势分析
  • 肿瘤学
  • 自体免疫疾病
  • 感染疾病
  • 心血管疾病
  • 代谢紊乱
  • 神经病学
  • 其他的

第六章 生物製药契约製造市场：按地区、产品和适应症的估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030 年市场规模及预测趋势分析
  • 北美洲
    • 按国家/地区，2018 年至 2030 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区，2018 年至 2030 年
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 按国家/地区，2018 年至 2030 年
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 按国家/地区，2018 年至 2030 年
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 参与者概述
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Wuxi Biologics.
    • FUJIFILM Diosynth BIoTechnologies.
    • Boehringer Ingelheim International GmbH
    • Lonza
    • Samsung Biologics
    • AbbVie Inc.
    • Catalent
    • Bioreliance（Merck KGaA）
    • Thermo Fisher Scientific Inc.
    • Eurofins Scientific
Product Code: GVR-4-68039-921-6

Biologics Contract Manufacturing Market Growth & Trends:

The global biologics contract manufacturing market size is expected to reach USD 57.59 billion by 2030, registering a CAGR of 10.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The global market was growing efficiently during the COVID-19 pandemic. This is due to a rise in R&D activities for the development of COVID-19 vaccines. In addition, there has been an expansion in manufacturing facilities to control the spread of the disease. For instance, in November 2021, Lonza announced that it has decided to expand its microbial development laboratories in Switzerland to support the company's upcoming projects.

It is believed that post-pandemic there will be numerous fundamental changes. There will be an increase in the production and manufacturing efforts for the development of vaccines and therapeutics against the coronavirus and a rise in digital capabilities across all their operating units. These initiatives will help them in joint planning with pharma clients in building more strategic partnerships. For instance, in January 2022, Lonza launched a technology that will be used for the discovery and design of antibodies that are biospecific and this technology will be called bYlok(TM). The outsourcing of drugs or biologics manufacturing is rapidly increasing around the world.

Pharmaceutical and biotechnology companies concentrate on their core projects while reducing the operational costs associated with manufacturing drugs or biologics. Contract Manufacturing Organizations (CMOs) are specialized and experienced in conducting the entire process of manufacturing. In-house manufacturing of biologics is difficult as it is a complex process and involves many resources. CMOs link the demand and supply gap by focusing on improving the drug discovery process resulting in faster availability of biologics for patients. Hence, due to these factors, outsourcing activities are rapidly increasing.

Biologics Contract Manufacturing Market Report Highlights:

  • Based on products, the MABs segment accounted for the largest revenue share in 2024 as MABs are used in the treatment of a wide range of diseases, such as cancer, infectious diseases, asthma, and auto-immune diseases
  • Based on indications, the oncology segment dominated the market in 2024 with the largest revenue share. The main factor responsible for the high segment share is the increased number of cancer cases
  • North America dominated the global market in 2024 due to the increased outsourcing services for manufacturing drugs & biologics and high R&D expenditure in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Indication
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Biologics Contract Manufacturing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Biologics Contract Manufacturing Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Monoclonal Antibodies (mAbs)
    • 4.4.1. Monoclonal Antibodies (mAbs) Market, 2018 - 2030 (USD Million)
  • 4.5. Recombinant Proteins
    • 4.5.1. Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 4.6. Vaccines
    • 4.6.1. Vaccines Market, 2018 - 2030 (USD Million)
  • 4.7. Antisense, RNAi, & Molecular Therapy
    • 4.7.1. Antisense, RNAi, & Molecular Therapy Market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Biologics contract manufacturing Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2024 & 2030
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 5.4. Oncology
    • 5.4.1. Oncology Market, 2018 - 2030 (USD Million)
  • 5.5. Autoimmune Diseases
    • 5.5.1. Autoimmune Diseases Market, 2018 - 2030 (USD Million)
  • 5.6. Infectious Diseases
    • 5.6.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 5.7. Cardiovascular Diseases
    • 5.7.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
  • 5.8. Metabolic Diseases
    • 5.8.1. Metabolic Diseases Market, 2018 - 2030 (USD Million)
  • 5.9. Neurology
    • 5.9.1. Neurology Market, 2018 - 2030 (USD Million)
  • 5.10. Others
    • 5.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Biologics Contract Manufacturing Market: Regional Estimates & Trend Analysis by Product and Indication

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Sweden Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Norway Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. Australia Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Thailand
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Thailand Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. South Korea
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. South Korea Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Wuxi Biologics.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. FUJIFILM Diosynth Biotechnologies.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Boehringer Ingelheim International GmbH
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Lonza
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Samsung Biologics
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. AbbVie Inc.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Catalent
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Bioreliance (Merck KGaA)
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Thermo Fisher Scientific Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Eurofins Scientific
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global biologics contract manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 5 Global biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 6 North America biologics contract manufacturing market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 8 North America biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 9 U.S. biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 10 U.S. biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 11 Canada biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 12 Canada biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 13 Mexico biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 14 Mexico biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 15 Europe biologics contract manufacturing market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 17 Europe biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 18 UK biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 19 UK biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 20 Germany biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 21 Germany biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 22 France biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 23 France biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 24 Italy biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 25 Italy biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 26 Spain biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 27 Spain biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Denmark biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 29 Denmark biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 30 Sweden biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 31 Sweden biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 32 Norway biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 33 Norway biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific biologics contract manufacturing market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 37 Japan biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 38 Japan biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 39 China biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 40 China biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 41 India biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 42 India biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 43 Australia biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 44 Australia biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 45 Thailand biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 46 Thailand biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 47 South Korea biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 48 South Korea biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 49 Latin America biologics contract manufacturing market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 51 Latin America biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 52 Brazil biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 53 Brazil biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 54 Argentina biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 55 Argentina biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Biologics contract manufacturing market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 59 South Africa biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 60 South Africa biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 63 UAE biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 64 UAE biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 65 Kuwait biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 66 Kuwait biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Biologics contract manufacturing market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market snapshot
  • Fig. 8 Product and indication outlook (USD Million)
  • Fig. 9 Competitive landscape
  • Fig. 10 Biologics contract manufacturing market dynamics
  • Fig. 11 Biologics contract manufacturing market: Porter's five forces analysis
  • Fig. 12 Biologics contract manufacturing market: PESTLE analysis
  • Fig. 13 Biologics contract manufacturing market: Product segment dashboard
  • Fig. 14 Biologics contract manufacturing market: Product market share analysis, 2024 & 2030
  • Fig. 15 Monoclonal Antibodies (mAbs) market, 2018 - 2030 (USD Million)
  • Fig. 16 Recombinant proteins market, 2018 - 2030 (USD Million)
  • Fig. 17 Vaccines market, 2018 - 2030 (USD Million)
  • Fig. 18 Antisense, RNAi, & molecular therapy market, 2018 - 2030 (USD Million)
  • Fig. 19 Others market, 2018 - 2030 (USD Million)
  • Fig. 20 Biologics contract manufacturing market: Indication segment dashboard
  • Fig. 21 Biologics contract manufacturing market: Indication market share analysis, 2024 & 2030
  • Fig. 22 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 23 Autoimmune diseases market, 2018 - 2030 (USD Million)
  • Fig. 24 Infectious diseases market, 2018 - 2030 (USD Million)
  • Fig. 25 Cardiovascular diseases market, 2018 - 2030 (USD Million)
  • Fig. 26 Metabolic diseases market, 2018 - 2030 (USD Million)
  • Fig. 27 Neurology market, 2018 - 2030 (USD Million)
  • Fig. 28 Others market, 2018 - 2030 (USD Million)
  • Fig. 29 Biologics contract manufacturing market revenue, by region
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 North America biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. country dynamics
  • Fig. 34 U.S. biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada country dynamics
  • Fig. 36 Canada biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico country dynamics
  • Fig. 38 Mexico biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 39 Europe biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 40 UK country dynamics
  • Fig. 41 UK biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 42 Germany country dynamics
  • Fig. 43 Germany biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 44 France country dynamics
  • Fig. 45 France biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 46 Italy country dynamics
  • Fig. 47 Italy biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 48 Spain country dynamics
  • Fig. 49 Spain biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 50 Denmark country dynamics
  • Fig. 51 Denmark biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden country dynamics
  • Fig. 53 Sweden biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 56 Asia Pacific biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 57 Japan country dynamics
  • Fig. 58 Japan biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 59 China country dynamics
  • Fig. 60 China biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 61 India country dynamics
  • Fig. 62 India biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 63 Australia country dynamics
  • Fig. 64 Australia biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 65 Thailand country dynamics
  • Fig. 66 Thailand biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea country dynamics
  • Fig. 68 South Korea biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 69 Latin America biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 70 Brazil country dynamics
  • Fig. 71 Brazil biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 72 Argentina country dynamics
  • Fig. 73 Argentina biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 74 MEA biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 75 South Africa country dynamics
  • Fig. 76 South Africa biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 77 Saudi Arabia country dynamics
  • Fig. 78 Saudi Arabia biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 79 UAE country dynamics
  • Fig. 80 UAE biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 81 Kuwait country dynamics
  • Fig. 82 Kuwait biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 83 Company categorization
  • Fig. 84 Company market position analysis
  • Fig. 85 Strategic framework